Understanding PD
Parkinson’s disease (PD) is a chronic, progressive neurological disease. With no confirmed diagnostic test and no cure, it presents a plethora of complex challenges. TPA is rising to the occasion by researching investigational products that target the motor symptoms of the disease to improve everyday life.
Originally dubbed “shaking palsy,” Parkinson’s disease was first medically described as a neurological symptom by James Parkinson in 1817.1 PD is a chronic, progressive neurological disease characterized by a loss of dopamine-producing neurons in the brain.2 Early symptoms include resting tremors, dragging of legs, slowness, “weakness” of limbs and difficulty using hands.
In many instances, the PD process starts long before it is detected.3 By the time someone is finally diagnosed with this silently progressive disease, they will have already lost 60-80% of the dopaminergic neurons (DAn) responsible for controlling multiple brain functions. The ability to regulate voluntary movements and behavioral processes (such as reward, addiction, mood and stress) becomes precarious.
The motor and non-motor symptoms of PD lead to a deluge of changes and challenges to patient lifestyle. Employment, hospitalizations, financial issues and the ability to be self-sufficient are all pressing issues. Parkinson’s Disease Psychosis (PDP) adds to the complications, with between 20-40% of people with PD reporting hallucinations or delusions as symptoms.4
The impact of Parkinson’s disease on patients and the people who care for them is immense. In the future, our hope is that treatments will have the power to save or replace these missing dopaminergic neurons. However, at present, treatments seek to target the motor and non-motor symptoms and improve quality of life.
people living with PD worldwide5
in the U.S., with estimated increase of 20% by 20305
most common neurodegenerative disease in the U.S.3
This Disease
PD presents a plethora of challenges; we’re ready to meet them. In addition to researching and developing life-changing treatments, TPA is committed to education that increases “fluency” in PD.
Learn More- Goetz CG. The history of Parkinson’s disease: early clinical descriptions and neurological therapies. Cold Spring Harb Perspect Med. 2011;1(1):a008862. doi: 10.1101/cshperspect.a008862. PMID: 22229124; PMCID: PMC3234454.
- Wong SL, Gilmour H, Ramage-Morin PL. Parkinson’s disease: prevalence, diagnosis and impact. Health Rep. 2014;25(11):10-14. PMID: 25408491.
- National Institute of Neurological Disorders and Stroke. Parkinson’s Disease: Challenges, Progress, and Promise. September 30, 2015. NIH Publication No. 15-5595
- Parkinson’s Foundation. Hallucinations/delusions. https://www.parkinson.org/understanding-parkinsons/non-movement-symptoms/hallucinations-delusions
- Parkinson’s Foundation. Statistics. https://www.parkinson.org/understanding-parkinsons/statistics
Registration of Clinical Trial Information and Disclosure of Results
a. Registration of our clinical trial information, and disclosure of results, to clinical trial registries
TPA will register and disclose information on publicly accessible clinical trial registries such as ClinicalTrials.gov regarding clinical trials that are being conducted or have been conducted.
b. Disclosure of clinical trial summary results
TPA will disclose the results from clinical trials in patients that form part of the submission package for products approved in the United States. Results will not be disclosed if TPA decides that disclosure may lead to identification of clinical trial participants. Results may not be disclosed under any of the following conditions:
- A third party, such as a company involved in joint development, has not agreed to disclosure.
- Disclosure may interfere with publication in medical journals.
- Disclosure may interfere with the protection of intellectual property rights.